STOCK TITAN

Masami Iijima discloses Takeda (TAK) share and RSU holdings in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD director Masami Iijima has filed an initial ownership report. The filing shows direct ownership of 12,801 Ordinary Shares and Tax Obligation Awards linked to 2,152, 2,392 and 2,280 underlying Ordinary Shares. It also notes 6,400 restricted stock units that vest in tranches of 2,100, 2,200 and 2,100 shares on June 1, 2026, 2027 and 2028, respectively. Each Tax Obligation Award is economically equivalent to one Ordinary Share and is settled in cash at vest primarily to cover tax obligations.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Iijima Masami

(Last)(First)(Middle)
2-1, OTEMACHI 1-CHOME
CHIYODA-KU

(Street)
TOKYO100-8631

(City)(State)(Zip)

JAPAN

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares12,801(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Tax Obligation Award06/01/202606/01/2026Ordinary Shares2,152(2)D
Tax Obligation Award06/01/202706/01/2027Ordinary Shares2,392(2)D
Tax Obligation Award06/01/202806/01/2028Ordinary Shares2,280(2)D
Explanation of Responses:
1. Includes an award of 6,400 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares) and June 1, 2028 (2,100 shares).
2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Remarks:
Exhibit 24 Power of Attorney
/s/ Max Heuer, by power of attorney, for Masami Iijima03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Masami Iijima’s Form 3 filing for TAK reveal?

The Form 3 shows Masami Iijima’s initial ownership in Takeda, including 12,801 Ordinary Shares, several Tax Obligation Awards, and 6,400 restricted stock units vesting between 2026 and 2028. It is a baseline disclosure of existing equity-linked interests.

How many Takeda (TAK) Ordinary Shares does Masami Iijima hold directly?

Masami Iijima holds 12,801 Ordinary Shares directly. This figure represents the reported direct equity position in Takeda at the time of the Form 3, separate from derivative interests such as restricted stock units and Tax Obligation Awards tied to future vesting events.

What are the Tax Obligation Awards reported in the Takeda (TAK) Form 3?

The Tax Obligation Awards are derivative awards economically equivalent to one Ordinary Share each. Upon vesting, they convert into cash payments based on the then-current Ordinary Share price, primarily to cover tax obligations, rather than delivering additional Takeda shares to the reporting person.

How many restricted stock units (RSUs) are included in Masami Iijima’s Takeda holdings?

The filing states that 6,400 restricted stock units are included. Each RSU represents a contingent right to receive one Ordinary Share, with vesting scheduled in three tranches over 2026, 2027, and 2028, subject to the specified vesting dates and conditions.

When do Masami Iijima’s Takeda (TAK) RSUs vest?

The RSUs vest in three installments: 2,100 shares on June 1, 2026, 2,200 shares on June 1, 2027, and 2,100 shares on June 1, 2028. Each vested RSU delivers one Ordinary Share, expanding equity ownership over time as vesting occurs.

Does Masami Iijima’s Form 3 indicate recent buying or selling of Takeda shares?

No explicit buying or selling is indicated in the data provided. The entries are characterized as holdings with unknown transaction codes, making this Form 3 primarily a snapshot of existing ownership and derivative awards rather than a record of recent market trades.
Takeda Pharm

NYSE:TAK

View TAK Stock Overview

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

57.56B
3.16B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo